Myomo

MYO

Market cap $42.9M

Myomo, Inc. (MYO) Presents at IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 Transcript

BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced its participation in the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026, taking place June 23–24, 2026. President and Chief Executive Officer Paul Gudonis and Chief Financial Officer David Henry will deliver a presentati.

Myomo (MYO) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced its participation in two upcoming investor conferences. On May 20, Myomo's President and Chief Executive Officer Paul Gudonis and Chief Financial Officer David Henry will participate virtually in a fireside chat as part of Alliance Global P.

BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Joseph M. (“Joe”) Manko Jr. as a director effective May 9, 2026, to serve until the 2027 annual meeting of stockholders. With this appointment, Myomo has seven directors. Mr. Manko is an accomplished investor with over 25.

Myomo (MYO) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Myomo, Inc. (MYO) Q1 2026 Earnings Call Transcript

Myomo, Inc. (MYO) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to a loss of $0.08 per share a year ago.

BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months ended March 31, 2026. “Earlier this year we established four success pillars for 2026, including growing revenue from recurring patient sources, increasing market access, demonstrating operating leverag.

BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO), a wearable medical robotics company and manufacturer of the MyoPro® powered arm brace, announces expanded access to the MyoPro device through Ottobock Care clinics nationwide. Ottobock Care will offer the MyoPro through its clinics across the country, helping individuals with upper extremity impairment caused by stroke, brachial plexus injury, or other neurological conditions regain function and improve quality of life. “The.